64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Launched by LANTHEUS MEDICAL IMAGING · Mar 1, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging agent called 64Cu-LNTH-1363S, which is designed to help doctors see certain types of cancer better during scans. Specifically, the study is looking at patients with metastatic sarcoma and gastrointestinal tract cancers, such as esophageal, gastric, pancreatic, and colorectal cancers. The main goals are to check how safe this imaging agent is, find the right dose for the best results, and see how it compares to standard methods of examining cancer.

To participate, patients must be at least 18 years old and have a confirmed diagnosis of one of the cancers being studied. They should also have the ability to provide tissue samples from their tumors. Women who can become pregnant need to have a negative pregnancy test and use birth control, while men need to avoid fathering a child during the study. Participants can expect to undergo some imaging tests and provide tissue samples, and they will be closely monitored for safety throughout the trial. It's important to note that those with certain health issues or who have had recent cancer treatments may not be eligible.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: Part 1
• Patients are eligible to be included in the study only if all of the following criteria apply:
• • 1. Patient must be ≥ 18 years of age and must have provided written informed consent.
• • 2. Patients with suspected FAP-expressing metastatic sarcoma.
• • 3. Patients must have histological, pathological, and/or cytological confirmation of a metastatic sarcoma (e.g., undifferentiated pleomorphic sarcoma, liposarcoma, Leiomyosarcoma, myxofibrosarcoma, solitary fibrous tumor, Ewing's sarcoma, synovial sarcoma, sarcoma not otherwise specified, osteosarcoma).
• • 4. Patients must be willing to consent to provide sufficient and adequate archived tumor tissue samples (formalin fixed, paraffin embedded sample), preferably from a biopsy of a tumor lesion obtained either at the time of or after the diagnosis of disease; if archival tissue sample is unavailable, a new biopsy should be performed on the most accessible lesion(s) to obtain the tumor tissue sample.
• • 5. Adequate renal function as determined by a calculated creatinine clearance ≥ 60 mL/min (Cockcroft Gault equation).
• • 6. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP must agree to use a highly effective method of contraception during the study and for 28 days after the last injection of the study drug.
• • 7. Male subjects who are able to father a child must agree to avoid impregnating a partner, to adhere to a highly effective method of contraception and to not donate sperm during the study and for 28 days after the last injection of the study drug.
• • Inclusion Criteria: Part 2
• • 1. Patients must be ≥ 18 years of age and must have provided written informed consent.
• • 2. Patients must have histological, pathological, and/or cytological confirmation of a sarcoma or GIT cancers e.g., esophageal, gastric, pancreatic, colorectal cancer.
• • 3. Patients must have suspected FAP expressing sarcoma or GIT cancers and planned for surgery within 60 days (from study imaging).
• • 4. Patients must be willing to consent to provide sufficient and adequate tumor tissue samples (formalin fixed, paraffin embedded sample), from their planned surgery after participating in study imaging.
• • 5. Adequate renal function as determined by a calculated creatinine clearance ≥ 60 mL/min (Cockcroft Gault equation).
• • 6. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP must agree to use a highly effective method of contraception during the study and for 28 days after the last injection of the study drug.
• • 7. Male subjects who are able to father a child must agree to avoid impregnating a partner, to adhere to a highly effective method of contraception and to not donate sperm during the study and for 28 days after the last injection of the study drug.
• • Exclusion Criteria: Part 1
• Patients are excluded from the study if any of the following criteria apply:
• • 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation.
• • 2. Known pregnancy or breastfeeding.
• • 3. Any PET scan done within 10 physical half-lives of the PET agent prior to receiving study intervention.
• • 4. They are participating as patients in another clinical study with an Investigational Product or another systemic therapy administered in the last 3 weeks.
• • 5. Has undergone or plans to undergo PET or single-photon emission computerized tomography (SPECT) imaging with any other FAPi imaging agent within 6 months prior to or after participating in this trial.
• • 6. History of QT/QTc interval prolongation, a marked baseline QT/QTc interval prolongation (e.g., repeated demonstration of a QTc interval, calculated with Fridericia's correction, \> 450 milliseconds) or taking medications known to cause QT/QTc prolongation.
• • 7. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome).
• • 8. Have history of QT prolongation or is taking a medication known to cause QT prolongation.
• • Exclusion Criteria: Part 2
• • 1. Patients who have received or are scheduled to receive neoadjuvant anti-cancer therapy.
• • 2. Evidence of metastatic or advanced, inoperable disease.
• • 3. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation.
• • 4. Known pregnancy or breastfeeding.
• • 5. Any PET scan done within 10 physical half-lives of the PET agent prior to receiving study intervention.
• • 6. They are participating as patients in another clinical study with an Investigational Product or another systemic therapy administered in the last 3 weeks.
• • 7. Has undergone or plans to undergo PET or SPECT imaging with any other FAPi imaging agent within 6 months prior to or after participating in this trial.
• • 8. History of QT/QTc interval prolongation, a marked baseline QT/QTc interval prolongation (e.g., repeated demonstration of a QTc interval, calculated with Fridericia's correction, \> 450 milliseconds) or taking medications known to cause QT/QTc prolongation.
• • 9. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)
• • 10. Have history of QT prolongation or is taking a medication known to cause QT prolongation.